03 · What You Need to Know
First confirm that the approval actually expired
Before declaring a lapse, verify the study's oversight requirements.
This matters because not all contemporary research operates under annual expiration. Under the U.S. 2018 Common Rule, routine continuing review is not required for certain categories of research unless the IRB determines otherwise. A study with no annual continuing-review requirement has not "expired" merely because twelve months have passed.
Conversely, another study may have an explicit approval end date or continuing-review requirement imposed by the committee, another regulatory framework, or institutional policy.
Check the approval letter, subsequent determinations, and committee records before deciding what status applies.
A lapse can occur even when renewal materials were submitted
Under OHRP's continuing-review guidance for research governed by the older HHS requirements, a lapse occurs when required continuing review and reapproval have not occurred by the expiration date. The guidance states that the regulations provide no grace period extending research beyond that date.
Submitting the renewal package therefore did not itself extend approval under that framework.
Other committees may use different procedures. The practical lesson is universal enough: do not assume "renewal pending" means "approval extended."
New participant enrollment usually becomes the clearest stop point
OHRP's guidance states that when approval lapses under the framework it addresses, enrollment of new participants cannot occur after expiration.
That includes more than simply signing a consent form if earlier recruitment or screening activities constitute research under the approved protocol.
When a lapse is discovered, pause before approaching additional prospective participants until the responsible committee clarifies what is authorized.
Ongoing participant activities may also need to stop
OHRP's older continuing-review guidance states that all research activities involving human subjects must stop after IRB approval expires unless continuation is determined to be in the best interests of already enrolled participants.
This can include interventions, research assessments, interviews, questionnaires, specimen collection, and other participant-facing research activities.
Do not decide that a scheduled visit is harmless enough to continue merely because it was arranged before expiration.
Participant welfare can require an exception to stopping
Stopping research immediately is not always the safest action for someone already enrolled.
OHRP gives examples in which continued participation during a lapse may be appropriate because the research intervention offers a prospect of direct benefit or because withholding the intervention could increase risk to the participant. Its guidance allows an initial best-interest determination to be made by the investigator, potentially in consultation with the participant's treating physician, followed as soon as possible by a request for confirmation that the IRB agrees.
This is a narrow participant-protection principle within that framework, not permission to keep the study running because interruption would be inconvenient.
Watch Out
"Participants are already enrolled" does not itself justify continuing research during a lapse. The relevant question is whether stopping particular activities would adversely affect participant welfare under the applicable rules and committee determination.
Distinguish research procedures from safety or clinical care
A participant may still require clinical care, safety monitoring, or another protective action even when research authorization has lapsed.
Stopping research should not mean abandoning participants or withholding care needed to protect them. The difficult part is distinguishing activities necessary for participant welfare from activities conducted primarily to generate research data.
For an interventional study, this may require immediate consultation with the ethics committee, sponsor, treating clinicians, or other responsible authorities.
What about data already collected?
Do not assume that an approval lapse automatically requires destruction of data collected while approval was valid.
The handling of previously collected information depends on the protocol, committee instructions, applicable regulations, and whether ongoing analysis itself remains an activity subject to continuing oversight.
Likewise, do not assume you can continue collecting new data simply because the participant interaction has already occurred. Analysis of existing data and acquisition of new participant information are different activities.
Ask the ethics office what may continue during the lapse.
What if the only remaining activity is data analysis?
This is precisely where current regulatory distinctions matter.
Under the U.S. 2018 Common Rule, certain research that has progressed to data analysis, including analysis involving identifiable private information or identifiable biospecimens, may not require continuing review unless the IRB determines otherwise. Research eligible for expedited review likewise generally does not require continuing review under those requirements.
Older approval frameworks and other regulatory systems may differ. Do not apply legacy lapse rules to a study that no longer has a continuing-review obligation.
Notify the ethics office promptly
Once a genuine lapse is discovered, do not wait until the renewal meeting to mention it.
Tell the responsible office what happened, when approval expired, what activities have occurred since expiration, whether any participants remain active, and whether stopping any procedure could affect participant welfare.
The committee may need enough information to determine the immediate restrictions, whether any activity constitutes a protocol deviation or noncompliance, and what is required for reapproval.
Document what occurred during the lapse
Construct an accurate timeline.
Expiration
Record the date and time at which approval ceased under the applicable procedure.
Discovery
Record when the research team recognized the lapse.
Activities
Identify recruitment, consent, interventions, follow-up, data collection, or other research activities that occurred after expiration.
Participants
Identify who was affected and whether any participant-safety concern exists.
Corrective action
Document what was stopped, whom you notified, and what steps were taken to prevent recurrence.
Do not alter dates or reconstruct the record to make the lapse appear shorter. An accurate timeline is necessary for appropriate oversight.
A lapse is not necessarily the same as suspension or termination
Under OHRP's older HHS continuing-review guidance, automatic expiration because continuing review was not completed is not itself treated as an IRB suspension or termination of approval.
That distinction can matter for regulatory reporting. However, repeated or deliberate failures to meet continuing-review requirements may raise separate concerns about serious or continuing noncompliance under that framework.
Use your committee's terminology rather than labeling the event yourself.
Reapproval does not make unauthorized activity retroactively approved
If the committee subsequently reapproves the study, that restores prospective authorization according to the new determination.
It does not change the historical fact that activities conducted during a lapse may have occurred without current approval.
The committee may need to decide how those activities and resulting data should be handled under its policies. Do not describe them retrospectively as approved simply because the study is approved again.
Reapproval may establish a new review date
Under OHRP's older continuing-review guidance, when a lapsed study is subsequently reapproved, the IRB may establish a new anniversary date or approve for a shorter interval in order to retain the previous review schedule.
Again, other committees may handle this differently. Record the new date assigned by the committee rather than assuming the original calendar remains unchanged.
Find out why the lapse happened
Once immediate participant protection and reapproval are addressed, correct the process failure.
Was the deadline never entered in the project calendar? Did responsibility shift when staff changed? Were renewal materials submitted too late? Did the team assume the ethics office would send a reminder? Did the investigator mistakenly believe approval of an amendment reset the expiration date?
The corrective action should match the cause.
OHRP recommends administrative tracking procedures to minimize unintended expiration and places responsibility on investigators to provide continuing-review information in a timely manner where continuing review is required.
The easiest lapse to manage is the one prevented
When your approval has a continuing-review or expiration date, build reminders far enough ahead to prepare, submit, and allow the committee to complete review.
One reminder on the expiration date is not a monitoring system. It is a notification that the monitoring system has already failed.
